Chase Kempinski | Chief Executive Officer
EVAX Inc.

Chase is the CEO and co-founder of Enepret Inc. He earned his doctorate degree at the University of Kentucky studying and engineering the biosynthesis of triterpene oils, like squalene. After advancing a yeast system to produce triterpene oils developed in his adviser's (Dr. Joe Chappell) laboratory, they founded the company in 2017. He led preclinical studies evaluating these yeast-produced triterpene oils in emulsion adjuvants leading to the first publication demonstrating the utility of synthetic biology-derived ingredients in a vaccine. Enepret and its subsidiary, EVAX Inc., are focused on providing high-purity, sustainable, and limitless triterpene oils and GMP emulsion adjuvants (EVAX-S and EVAX-B) to vaccine developers. Chase is leading commercialization of these products, raising over $3.3 million in non-dilutive capital (including NIH National Institute of Allergy and Infectious Diseases STTR grant and SBIR contract funding), and establishing the path to offer GMP products. We are seeking partners to utilize our triterpene oils and adjuvant formulations.